Why Drug Interactions Matter for Ketamine
Ketamine is a pharmacologically complex molecule that interacts with multiple receptor systems and drug-metabolizing enzymes. Many patients starting ketamine therapy are already taking multiple psychiatric or medical medications — because the very population seeking ketamine has often tried and failed multiple prior treatments.
Understanding how these medications interact with ketamine is essential for safe prescribing and for patients who want to engage intelligently with their treatment plan. Make sure to disclose all medications to your provider — our guide on what to tell your doctor covers the full intake checklist.
MAOI Antidepressants
Severity: SERIOUS — discuss with prescriber before starting or stopping
Monoamine oxidase inhibitors (phenelzine, tranylcypromine, isocarboxazid, selegiline at high doses) interact dangerously with many drugs. The concern with ketamine:
Ketamine stimulates release of serotonin, norepinephrine, and dopamine. MAOIs prevent breakdown of these monoamines. The combination can produce serotonin syndrome — a potentially life-threatening condition with features including hyperthermia, autonomic instability, muscular rigidity, agitation, and altered consciousness.
Clinical management: Most ketamine prescribers will not prescribe ketamine to patients on MAOIs. This is one of the absolute contraindications for ketamine therapy. If an MAOI must be discontinued before starting ketamine, appropriate washout periods apply (2 weeks for most MAOIs; 5 weeks for fluoxetine; 14 days after stopping ketamine before restarting an MAOI).
Benzodiazepines
Severity: MODERATE — affects efficacy; combined sedation risk
Benzodiazepines (alprazolam, diazepam, lorazepam, clonazepam, etc.) interact with ketamine in two important ways:
Efficacy Impact
Benzodiazepines enhance GABA-A receptor activity, which partially antagonizes the neurobiological effects of ketamine. Clinical studies and observations have consistently shown that patients taking regular benzodiazepines have blunted responses to ketamine's antidepressant and psychoactive effects — sometimes significantly so.
This means:
- Patients on regular benzodiazepines may need higher ketamine doses for equivalent therapeutic effect
- Clinicians evaluating response in benzodiazepine-using patients must account for this blunting effect
- Some protocols recommend dose-adjusted protocols or (with physician supervision) temporary benzodiazepine reduction before ketamine sessions
Sedation Risk
Combined sedation from benzodiazepines plus ketamine's dissociative effects can produce excessive sedation, respiratory depression, and impaired airway protection. This is particularly relevant for:
- Patients taking higher benzodiazepine doses
- Patients taking benzodiazepines acutely before a session (for anxiety management)
Using a benzodiazepine immediately before a ketamine session should be avoided unless specifically directed by the prescriber. If pre-session anxiety is a concern, discuss alternative strategies.
SSRIs and SNRIs
Severity: LOW to MODERATE — generally safe; mild interaction
Selective serotonin reuptake inhibitors (SSRIs: fluoxetine, sertraline, escitalopram, paroxetine) and serotonin-norepinephrine reuptake inhibitors (SNRIs: duloxetine, venlafaxine) are the most commonly taken concurrent medications in ketamine patients.
The interaction is generally minor:
- Theoretical serotonin syndrome risk exists but is very low at therapeutic ketamine doses — serotonin syndrome from this combination has not been reliably documented in clinical case reports at standard troche doses
- Some evidence suggests SSRIs may mildly blunt ketamine's antidepressant effects
- Continuing SSRIs during ketamine therapy is generally recommended — the combination may produce additive benefits and may help maintain ketamine's neuroplastic effects
Clinical guidance: Do not stop SSRIs before starting ketamine without prescriber direction. The combination is used routinely and considered safe.
Tricyclic Antidepressants (TCAs)
Severity: MODERATE — cardiovascular monitoring important
TCAs (amitriptyline, nortriptyline, imipramine, etc.) have anticholinergic effects and QTc-prolonging potential. Combined with ketamine's cardiovascular stimulatory effects, there is potential for additive blood pressure effects and, theoretically, additive arrhythmia risk in patients with cardiac vulnerability.
Clinical guidance: Patients on TCAs should have an ECG reviewed before starting ketamine and enhanced cardiovascular monitoring during sessions.
Stimulants (Amphetamines, Methylphenidate)
Severity: MODERATE — cardiovascular concerns
Stimulant medications (Adderall, Vyvanse, Ritalin, Concerta) used for ADHD have sympathomimetic effects that overlap with ketamine's cardiovascular profile. Combined use can amplify blood pressure and heart rate elevation beyond what either drug alone would produce.
Clinical guidance:
- Disclose all stimulant medications to your prescriber
- Consider timing: some providers recommend not taking stimulants on session days or taking them earlier in the day before the session
- Enhanced blood pressure monitoring is warranted for patients on stimulants
Opioids
Severity: MODERATE — sedation, respiratory depression risk
Opioids and ketamine are commonly combined in clinical pain management — ketamine is often used to reduce opioid doses in patients with opioid-refractory pain or opioid-induced hyperalgesia. However, the combination carries additive sedation and respiratory depression risk at higher doses of both.
Clinical guidance:
- Patients on opioid therapy should disclose their full opioid regimen
- Session monitoring is particularly important for opioid users
- The combination is clinically used but requires dose-awareness and monitoring
Antipsychotics
Severity: LOW — blunting of effects; metabolic interactions
Antipsychotic medications (quetiapine, risperidone, aripiprazole, olanzapine, etc.) can blunt ketamine's dissociative effects by various mechanisms, depending on the specific antipsychotic. They may also affect the metabolism of ketamine through CYP enzyme interactions.
Clinical guidance: Patients on antipsychotics may require higher ketamine doses for equivalent therapeutic effect. Discuss with your prescriber — in some cases, the antipsychotic dosing schedule can be considered relative to session timing.
Anticonvulsants / Mood Stabilizers
Severity: VARIABLE
- Lithium: Generally compatible with ketamine; some clinicians believe lithium may have synergistic neuroprotective effects alongside ketamine. Monitor for lithium toxicity symptoms, as any illness that causes dehydration during ketamine therapy can elevate lithium levels.
- Valproate: Generally compatible; valproate has GABA-enhancing and glutamate-modulating effects that may interact mildly with ketamine.
- Lamotrigine: Some animal research suggests lamotrigine (which blocks voltage-gated sodium channels and reduces glutamate release) may blunt ketamine's antidepressant effects. Clinical significance in humans is uncertain.
- Carbamazepine/Oxcarbazepine: These are CYP3A4 inducers and can significantly accelerate ketamine metabolism, potentially reducing efficacy. Dose adjustments may be needed.
Cannabis
Severity: LOW to MODERATE — variable interaction
Cannabis has complex interactions with ketamine:
- THC-dominant cannabis may amplify dissociative effects unpredictably
- CBD has GABA-ergic and modest NMDA-modulatory effects
- Cannabis use on session days is generally discouraged due to the unpredictable combined effect
- Regular cannabis users may have altered baseline responses to ketamine
Clinical guidance: Disclose cannabis use. Avoid cannabis on session days. Discuss regular use with your prescriber.
Alcohol
Severity: MODERATE — additive CNS depression
Alcohol is a CNS depressant with GABA-A activity. Combined with ketamine, it can produce excessive sedation, respiratory depression, and impaired protective reflexes.
Clinical guidance: No alcohol on session days. No alcohol within 24 hours before a session. Regular heavy alcohol use warrants addiction medicine assessment before starting ketamine therapy.
Lamotrigine and Ketamine Interaction: A Note for TRD Patients
Some patients with TRD are on lamotrigine augmentation. The concern that lamotrigine might blunt ketamine's antidepressant effects (via glutamate pathway interaction) has influenced some providers to temporarily pause lamotrigine around ketamine sessions. The clinical evidence for this practice is modest; discuss with your prescriber rather than pausing lamotrigine independently.
CYP Enzyme Interactions
Ketamine is primarily metabolized by CYP3A4 and CYP2B6. Drugs that affect these enzymes can alter ketamine's plasma concentrations:
CYP3A4 inhibitors (can increase ketamine levels): Ketoconazole, itraconazole, erythromycin, clarithromycin, grapefruit juice
CYP3A4 inducers (can decrease ketamine levels): Rifampin, carbamazepine, phenytoin, St. John's Wort
If you are starting or stopping any of these medications, discuss with your prescriber — your ketamine dose may need adjustment.
Key Takeaways
- MAOIs are the most serious interaction risk — do not combine with ketamine without specialist guidance.
- Benzodiazepines blunt ketamine effects and increase sedation risk; avoid acutely before sessions.
- SSRIs/SNRIs are generally safe to continue; the combination is routinely used.
- Stimulants require cardiovascular monitoring; avoid on session days if prescribed.
- Cannabis and alcohol should be avoided on session days.
- Disclose ALL medications and supplements to your prescriber — this list is not exhaustive.
References
- StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
- PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
- MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
- SAMHSA: National Helpline — Substance Abuse and Mental Health Services Administration free treatment referral and information service
Share